HomeGBT • EPA
add
Guerbet SA
Previous close
€25.95
Day range
€25.85 - €26.40
Year range
€17.02 - €40.25
Market cap
335.64M EUR
Avg Volume
20.13K
P/E ratio
10.40
Dividend yield
1.92%
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 212.46M | 11.88% |
Operating expense | 154.24M | 6.80% |
Net income | 5.49M | 426.87% |
Net profit margin | 2.58 | 369.09% |
Earnings per share | — | — |
EBITDA | 30.21M | 49.72% |
Effective tax rate | 32.07% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 39.05M | 0.45% |
Total assets | 1.04B | 5.12% |
Total liabilities | 654.37M | 5.38% |
Total equity | 387.59M | — |
Shares outstanding | 12.61M | — |
Price to book | 0.84 | — |
Return on assets | 3.63% | — |
Return on capital | 4.78% | — |
Cash Flow
Net change in cash
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | 5.49M | 426.87% |
Cash from operations | 5.08M | 130.98% |
Cash from investing | -11.89M | 8.04% |
Cash from financing | 1.04M | -96.34% |
Net change in cash | -6.12M | -311.30% |
Free cash flow | 9.88M | 76.22% |
About
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.
In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters, formerly located in Villepinte, is currently located in Chicago, and its shares are included in the NASDAQ stock index.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015. Wikipedia
CEO
Founded
1926
Website
Employees
2,920
